Recent Company News

• 07:33 PM ET Aug 28, 2025
  

  Immutep reports FY NPAT (A$61.4M) vs FactSet (A$59.6M) [2 est, (A$61)-(58.2M)] (A$0.25, 0.00)

• 09:40 PM ET May 25, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 07:35 PM ET Aug 04, 2025
  

  Immutep receives positive feedback from FDA on late-stage clinical development of eftilagimod alfa in head and neck cancer with CPS <1 (A$0.26, 0.00)

• 06:33 PM ET Jul 29, 2025
  

  Immutep reports Q4 net cash used in operating activities (A$18.9M) - Appendix 4C (A$0.27, 0.00)

• 07:35 PM ET Jul 27, 2025
  

  Immutep abstracts for clinical trials evaluating efti accepted for presentation at ESMO Congress 2025 (A$0.26, 0.00)

• 09:58 PM ET Jun 25, 2025
  

  StreetAccount Summary - Australia unusual volume traders

• 06:39 PM ET Jun 22, 2025
  

  Immutep initial data from Phase I study of IMP761 shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg (A$0.24, 0.00)

• 06:32 PM ET May 25, 2025
  

  Immutep's Phase II trial evaluating efti with radiotherapy plus KEYTRUDA in neoadjuvant setting for resectable STS has met primary endpoint (A$0.30, 0.00)